You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR ABEMACICLIB

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for ABEMACICLIB

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01394016 ↗	A Phase 1 Study of LY2835219 In Participants With Advanced Cancer	Active, not recruiting	Eli Lilly and Company	Phase 1	2009-12-07	The purpose of this study is to determine a safe dose of LY2835219 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2835219 in this population. Efficacy measures will be used to assess the activity of LY2835219 in this population.
NCT01655225 ↗	A Study of LY3023414 in Participants With Advanced Cancer	Active, not recruiting	Eli Lilly and Company	Phase 1	2012-07-31	The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.
NCT01739309 ↗	Study of LY2835219 for Mantle Cell Lymphoma	Active, not recruiting	Eli Lilly and Company	Phase 2	2013-03-20	The purpose of this study is to estimate the disease control rate with abemaciclib for relapsed or refractory mantle cell lymphoma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for ABEMACICLIB

Condition Name

Chart
Table

Condition Name for ABEMACICLIB
Intervention	Trials
Breast Cancer	36
Metastatic Breast Cancer	20
Neoplasm Metastasis	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for ABEMACICLIB
Intervention	Trials
Breast Neoplasms	86
Neoplasms	26
Carcinoma	17
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for ABEMACICLIB

Trials by Country

Map
Table

Trials by Country for ABEMACICLIB
Location	Trials
United States	875
China	98
Spain	97
Germany	69
Italy	67
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for ABEMACICLIB
Location	Trials
Texas	50
California	46
Massachusetts	44
New York	42
Florida	40
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for ABEMACICLIB

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for ABEMACICLIB
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	20
Phase 2/Phase 3	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for ABEMACICLIB
Clinical Trial Phase	Trials
Recruiting	88
Not yet recruiting	32
Active, not recruiting	24
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ABEMACICLIB

Sponsor Name

Chart
Table

Sponsor Name for ABEMACICLIB
Sponsor	Trials
Eli Lilly and Company	100
National Cancer Institute (NCI)	19
Dana-Farber Cancer Institute	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for ABEMACICLIB
Sponsor	Trials
Industry	167
Other	130
NIH	19
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.